MEDICATION ACCESS BARRIERS FOR ELEXACAFTOR/TEZACAFTOR/IVACAFTOR-ELIGIBLE PEOPLE WITH CYSTIC FIBROSIS

被引：0
|
作者：
Dieni, O. [1 ]
Ryan, L. [1 ]
Stocks, A. [1 ]
Erdo, J. [1 ]
机构：
[1] Cyst Fibrosis Fdn, Bethesda, MD USA
来源：
PEDIATRIC PULMONOLOGY | 2020年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
811
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [21] Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Miller, Matthew J.
    Foroozan, Rod
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2022, 57 (01): : E6 - E10
  • [22] Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Anderson, Ashlee
    McCoy, Lindsey
    Pettit, Rebecca S.
    Wright, Brittany A.
    Lubsch, Lisa
    PEDIATRIC PULMONOLOGY, 2021, 56 (12) : 4053 - 4054
  • [23] A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis
    Kinsey, Laura
    Winterbottom, Hannah
    Hudson, Lydia
    Lal, Simon
    Jones, Andrew M.
    Burden, Sorrel
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2025,
  • [24] ADHERENCE TO NEBULISED THERAPIES IN PEOPLE WITH CYSTIC FIBROSIS STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (KAFTRIO)
    Howell, I. B.
    Tugwell, A.
    Bhaskaran, D.
    Bell, N. J.
    THORAX, 2021, 76 : A40 - A40
  • [25] Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis
    Westhoelter, D.
    Schumacher, F.
    Wuelfinghoff, N.
    Sutharsan, S.
    Strassburg, S.
    Kleuser, B.
    Horn, P. A.
    Reuter, S.
    Gulbins, E.
    Taube, C.
    Welsner, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [26] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [27] HOW ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IS CHANGING SPUTUM CULTURE COLLECTION FOR PEOPLE WITH CYSTIC FIBROSIS
    Pai, S.
    Villagomez, K.
    Dorsett, S.
    Guthrie, C. P.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S260 - S260
  • [28] Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis
    Furstova, Eva
    Dousova, Tereza
    Beranek, Jakub
    Libik, Malgorzata
    Fila, Libor
    Modrak, Martin
    Cinek, Ondrej
    Macek, Milan, Jr.
    Drevinek, Pavel
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : 243 - 245
  • [29] ANALYSIS OF ACCESS TO THE FIRST FILL OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN PEDIATRIC AND ADULT CYSTIC FIBROSIS PATIENTS
    Burrus, T.
    Loy, S.
    Teibel, H.
    Taylor, A.
    Sorgen, P.
    Pettit, R. S.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S247 - S247
  • [30] Elexacaftor/tezacaftor/ivacaftor treatment corrects the salt-losing phenotype in people with cystic fibrosis
    Leipziger, Jens
    Svendsen, Samuel
    Rousing, Amalie Quist
    Jensen-Fangel, Soren
    Bandulik, Sascha
    Warth, Richard
    Sorensen, Mads Vaarby
    Jeppesen, Majbritt
    Berg, Peder
    ACTA PHYSIOLOGICA, 2023, 239
12345